Quick Dispatch:
Your surmount-1 tirzepatide weight loss results SURMOUNT‐1 study design. This is a phase 3, multicenter, randomized, orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your surmount-1 tirzepatide weight loss results SURMOUNT‐1 study design. This is a phase 3, multicenter, randomized, ships.
Need Help?
Questions about surmount-1 tirzepatide weight loss results SURMOUNT‐1 study design. This is a phase 3, multicenter, randomized,, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for surmount-1 tirzepatide weight loss results SURMOUNT‐1 study design. This is a phase 3, multicenter, randomized, in your area.
SURMOUNT-1 (NEJM 2022) tested tirzepatide — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants
22.96
Time to weight plateau with tirzepatide treatment in the SURMOUNT‐1 and SURMOUNT‐4 clinical trials - Horn - 2025 - Clinical Obesity
20.37
Semaglutide vs. Tirzepatide for Obesity
24.88
Adults with obesity using tirzepatide maintain 'remarkable' weight loss at 88 weeks
24.53
Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial
25.89
Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity
24.49
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
20.87
